Advertisement
OtherCARDIOVASCULAR PHARMACOLOGY

Activation of Histamine H3 Receptors Inhibits Carrier-Mediated Norepinephrine Release in a Human Model of Protracted Myocardial Ischemia ,

Eiichiro Hatta, Keishu Yasuda and Roberto Levi
Journal of Pharmacology and Experimental Therapeutics November 1997, 283 (2) 494-500;

Abstract

During protracted myocardial ischemia, ATP depletion promotes Na+ accumulation in sympathetic terminals and prevents vesicular storage of norepinephrine (NE). This forces the reversal of the neuronal uptake1 transporter, and NE is massively released (carrier-mediated release). We had shown that histamine H3 receptors (H3Rs) modulate ischemic NE release in animals. We have now used a human model of protracted myocardial ischemia to investigate whether H3Rs may control carrier-mediated NE release. Surgical specimens of human atrium were incubated in anoxic conditions. NE release increased ∼7-fold within 70 min of anoxia. This release was carrier mediated because it was Ca++ independent and inhibited by the uptake1inhibitor desipramine. Furthermore, the Na+/H+exchanger (NHE) inhibitors ethyl-isopropyl-amiloride and HOE 642, and the Na+ channel blocker tetrodotoxin inhibited NE release, whereas the Na+ channel activator aconitine potentiated it. The selective H3R agonist imetit decreased NE release, an effect that was blocked by each of the H3R antagonists thioperamide and clobenpropit. Notably, imetit acted synergistically with ethyl-isopropyl-amiloride, HOE 642 and tetrodotoxin to reduce anoxic NE release. Thus, activation of H3R appears to result in an inhibition of both NHE- and voltage-dependent Na+ channels. Most importantly, endogenous histamine was released from the anoxic human heart, and thioperamide and clobenpropit each alone increased NE release, indicating that H3R become activated in myocardial ischemia. Our findings indicate that H3Rs are likely to mitigate sympathetic overactivity in the ischemic human heart and suggest new therapeutic strategies to alleviate dysfunctions associated with myocardial ischemia.

Previous work in our laboratory established the presence of heteroinhibitory H3Rs on adrenergic nerve endings in the heart of the guinea pig (Endou et al., 1994; Imamura et al., 1994), dog (Seyedi et al., 1996) and humans (Imamura et al., 1995). Once activated, these receptors attenuate NE exocytosis. The mechanism of this effect involves a Gi/Go protein and a decreased entry of Ca++ through N-type channels (Endou et al., 1994). A decreased PKC activity, resulting from a decreased phosphoinositide turnover (Cherifi et al., 1992) and diacylglycerol formation, may also play a role in the modulation of NE release associated with H3R activation (Imamura et al., 1995).

H3R activation also inhibits NE release in animal models of acute and protracted myocardial ischemia (Imamura et al., 1994, 1996). In the acute ischemia model, NE release is exocytotic and Ca++ dependent. In the protracted ischemia model, NE release is Ca++ independent, carrier mediated and much greater than that with acute ischemia (Imamura et al., 1994,1996). During protracted myocardial ischemia, ATP depletion promotes Na+ accumulation in sympathetic nerve endings and prevents the vesicular storage of NE. This forces the reversal of the neuronal uptake1 transporter from an inward to an outward direction, and NE is massively released (carrier-mediated release) (Dart and Du, 1993; Schömig, 1990). The mechanism of the H3R-induced attenuation of carrier-mediated NE release probably involves an inhibition of the NHE (Imamura et al., 1996). Such inhibition would reduce the intraneuronal accumulation of Na+ and therefore decrease the activity of the NE transporter in the outward direction.

Carrier-mediated NE release was recently described in an ischemic model in human cardiac tissue (Kurz et al., 1995). We used this model to test the hypothesis that H3R activation will inhibit carrier-mediated NE release in the human heart. Moreover, we were intrigued by the possibility that as in animal models (Imamuraet al., 1994, 1996; Levi et al., 1991; Wolff and Levi, 1986, 1988), endogenous histamine would also be released in the ischemic human heart, and, if so, in sufficient concentrations to activate H3R. Thus, the purpose of this investigation was to determine whether in the ischemic human heart, carrier-mediated NE release can be negatively modulated by activation of H3R by both exogenous and endogenous ligands and whether this action may be related to an inhibition of intraneuronal Na+ accumulation.

Materials and Methods

Source of human cardiac tissue.

Specimens of right atrium (i.e., surgical waste tissue) were obtained from 209 patients undergoing cardiopulmonary bypass (144 men and 65 women, age 64.9 ± 0.8 years; coronary artery bypass graft surgery, 173; valve replacement, 23; both, 13), following a protocol approved by our institutional review board. Seventy-three of the 186 bypass patients were chronically treated with beta adrenoceptor-blocking agents. Preoperative treatment with beta blockers did not affect the anoxic release of NE and/or histamine. At the time of surgery, a piece of atrial appendage measuring ∼1 cm3 was removed from the atriotomy site.

Incubation conditions.

The specimen was immediately transported to the laboratory in ice-cold oxygenated KHS of the following composition (mM): NaCl 118.2, KCl 4.83, CaCl22.5, MgSO4 2.37, KH2PO4 1.0, NaHCO3 25 and glucose 11.1. After removal of fat and connective tissue, the specimen was divided into several fragments (each weighing 23.3 ± 0.8 mg wet weight, measured at the end of incubation). Each fragment was incubated for 45 min at 37.5°C in 2 ml of KHS gassed with 95% O2 and 5% CO2(Po2 ∼550 mm Hg, pH 7.4) containing the monoamine oxidase inhibitor pargyline (1 mM). After the 45-min stabilization period, fragments were incubated for an additional 20 min in oxygenated KHS in the absence or presence of one or more pharmacological agents. When thioperamide or clobenpropit was used, it was added 15 min after the beginning of the stabilization period.

Induction of anoxia.

Anoxia was induced by incubating the atrial fragments for 10 to 70 min in glucose-free KHS gassed with 95% N2 and 5% CO2 and containing the reducing agent sodium dithionite (3 mM; Po2 ∼0 mm Hg, pH 7.3; anoxic period; in contrast, in the absence of sodium dithionite, Po2 was ∼70). Matched control fragments were incubated for an equivalent length of time with oxygenated KHS (normoxic NE release). When drugs were used, they were continued throughout the entire anoxic period.

NE assay.

Incubating media were assayed for NE by high-pressure liquid chromatography with electrochemical detection (Imamura et al., 1994). Perchloric acid and EDTA were added to samples to achieve final concentrations of 0.01 N and 0.025%, respectively. After a short period of storage (<2 weeks) at −70°C, the samples were thawed. The NE present in the effluent was adsorbed on acid-washed alumina adjusted at pH 8.6 with Tris-2% EDTA buffer and then extracted into 150 μl of 0.1 N perchloric acid. These final sample aliquots were kept frozen until injected onto a 3-μm ODS reverse-phase column (3.2 × 100 mm; Bioanalytical System, West Lafayette, IN) with an applied potential of 0.65 V. The mobile phase consisted of monochloroacetic acid (75 mM), Na2EDTA (0.5 mM), sodium octylsulfate (0.5 mM) and acetonitrile (1.5%) at pH 3.0. The flow rate was 1.0 ml/min. Dihydroxybenzylamine was added to each sample as an internal standard before alumina extraction and used for recovery calculation. The recovery of NE was 77%, and the detection limit was ∼0.2 pmol.

Histamine assay.

Incubating media containing SKF-91,488 (10 μM), a histamine N-methyltransferase inhibitor (Beaven and Shaff, 1979), were stored for a short period (<2 weeks) at ∼70°C. Samples were then thawed and assayed for histamine content with the use of a commercial enzyme immunoassay kit (Immunotech International, Westbrook, ME) (Imamura et al., 1994). The recovery of histamine was ∼100%, and the detection limit was ∼0.02 pmol.

Statistics.

Values are expressed as mean ± S.E. Analysis by analysis of variance was used followed by post hoc testing (Bonferroni’s test). Student’s t test was performed for paired observations. A value of P < .05 was considered statistically significant.

Drugs.

HOE 642 (4-isopropyl-3-methylsulfonylbenzoyl-guanidine methanesulfonate) was a gift of Hoechst Marion Roussel (Frankfurt, Germany). DMI hydrochloride (desipramine), histamine dihydrochloride, pargyline hydrochloride and sodium dithionite (Na2S2O4) were purchased from Sigma Chemical (St. Louis, MO). Aconitine, clobenpropit dihydrobromide, EIPA, imetit dihydrobromide,l-(−)-norepinephrine bitartrate, SKF-91,488 dihydrochloride, TTX and thioperamide maleate were purchased from Research Biochemicals International (Natick, MA). EIPA was initially dissolved in 99.8% DMSO; TTX and aconitine were initially dissolved in 95% ethanol, and further dilutions were made in KHS. At the concentrations used, DMSO and ethanol had no effect on any preparation in these studies. All other drugs were dissolved in KHS.

Results

Carrier-mediated NE release from the human myocardium.

The incubation of human right atrial tissue in glucose-free KHS in anoxic conditions (Po2 ∼0 mm Hg; pH 7.3), caused a pronounced time-dependent release of endogenous NE. As shown in figure1, after 50 min of anoxia, NE release increased ∼4.5-fold above basal level and reached a ∼7-fold maximum plateau after 60 to 70 min of anoxia. Maximum anoxic NE release was not modified in Ca++-free conditions (fig.2A). Furthermore, maximum anoxic NE release was not modified by 1 μM atropine (648 ± 105vs. 676 ± 141 pmol/g in the absence and presence of atropine, respectively; n = 5).

Figure 1
Figure 1

Time course of NE release from human right atrial tissue in anoxic conditions in the presence and absence of the neuronal uptake1 inhibitor DMI (100 nM) (see Materials and Methods). NE release in normoxic conditions is shown for comparison. Points are mean ± S.E.M. values of NE released into the incubation medium at the time indicated on the abscissa (n = 5–9; ** P < .01 from normoxic control; † P < .05 from both anoxic and normoxic control by analysis of variance followed bypost hoc Bonferroni’s test).

Figure 2
Figure 2

A, Anoxic NE release from human right atrial tissue in Ca++-free conditions. Bars represent the total NE released into the incubation medium during 70 min of anoxia in the absence (Ca++-free) and presence (Control) of 2.5 mM Ca++ (mean ± S.E.M.; n = 10; NS by paired t test). B, Blockade of anoxic NE release from human right atrial tissue by the NE uptake1 inhibitor DMI. Bars represent the total NE released during 70 min of anoxia in the absence (Control) and presence of DMI (100 nM) (mean ± S.E.M.;n = 9; * P < .05 by paired t test).

Because Ca++-independent NE release is consistent with a reversal of the NE transporter in an outward direction, we next assessed whether NE release would be affected by inhibition of the transporter. As shown in figures 1 and 2B, anoxic NE release was markedly reduced (i.e., by ∼40%) when human atrial tissue was incubated with the NE neuronal uptake1 inhibitor DMI (100 nM). Interestingly, after 20 min of anoxia, when NE release was only slightly greater than its normoxic control, DMI enhanced anoxic NE release by ∼35%.

Intracellular Na+ balance and carrier-mediated NE release.

Because the desipramine-induced inhibition suggested that anoxic NE release was carrier-mediated, a condition associated with increased intracellular Na+, we next investigated whether NE release would be affected by agents capable of interfering with intracellular Na+ accumulation. As shown in figure3, maximum anoxic NE release was markedly reduced (i.e., by ∼40%) when atrial tissue was incubated with the NHE inhibitors EIPA (10 μM; fig. 3A) and HOE 642 (10 μM; fig. 3B).

Figure 3
Figure 3

A, Blockade of anoxic NE release from human right atrial tissue by the NHE inhibitor EIPA. Bars represent the total NE released during 70 min of anoxia in the absence (Control) and presence of EIPA (10 μM) (mean ± S.E.M.; n = 13; * P < .05 by paired t test). B, Blockade of anoxic NE release from human right atrial tissue by the NHE inhibitor HOE 642. Bars represent the total NE released during 70 min of anoxia in the absence (Control) and presence of HOE 642 (10 μM) (mean ± S.E.M.; n = 6; ** P < .01 by paired ttest).

Because voltage-dependent Na+ channels may also contribute to increase intracellular Na+ in anoxic conditions, we subsequently determined whether NE release would be influenced by TTX. As shown in figure 4A, TTX (1 μM) significantly decreased maximum anoxic NE release (i.e., by ∼35%). Conversely, aconitine (100 nM), which prolongs Na+ channel conductance, markedly potentiated anoxic NE release (i.e., by ∼40%, fig. 4B).

Figure 4
Figure 4

A, Blockade of anoxic NE release from human right atrial tissue by the Na+ channel blocker TTX. Bars represent the total NE released during 70 min of anoxia in the absence (Control) and presence of TTX (1 μM) (mean ± S.E.M.;n = 10; ** P < .01 by paired t test). B, Potentiation of anoxic NE release from human right atrial tissue by the Na+ channel activator aconitine. Bars represent the total NE released during 70 min of anoxia in the absence (Control) and presence of aconitine (100 nM) (mean ± S.E.M.; n= 9; ** P < .01 by paired t test).

Activation of H3Rs and carrier-mediated NE release.

Because the previous findings implied that anoxic NE release was carrier mediated and likely associated with accumulation of Na+, we next investigated whether activation of prejunctional modulatory receptors would affect NE release in anoxic conditions. As shown in figure 5, the selective H3R agonist imetit (100 nM) markedly reduced maximum anoxic NE release (i.e., by 40–45%). The selective H3R antagonists thioperamide (300 nM) and clobenpropit (25 nM) each blocked the effect of imetit (fig. 5, A and B). Furthermore, thioperamide and clobenpropit each alone increased maximum anoxic NE release by 25% to 30% (fig. 5, A and B). In contrast, neither imetit nor thioperamide or clobenpropit modified NE release in normoxic conditions. NE release was 138.6 ± 21.4, 132.9 ± 16.8, 138.9 ± 24.5 and 135.1 ± 22.1 pmol/g in control normoxia and in normoxia in the presence of imetit, thioperamide and clobenpropit, respectively (mean ± S.E.M.; n = 10).

Figure 5
Figure 5

Blockade of anoxic NE release from human right atrial tissue by the selective H3R agonist imetit and its inhibition by the selective H3R antagonists thioperamide (thiop; A) and clobenpropit (CBP; B). Bars represent the total NE released into the incubation medium during 70 min of anoxia in the absence of drugs and in the presence of imetit alone (100 nM), thioperamide alone (300 nM), clobenpropit alone (25 nM) and imetit in combination with either thioperamide or clobenpropit (mean ± S.E.M.; n = 6–12; * P < .05 and ** P < .01 vs. control; † P < .05 and †† P < .01vs. imetit by analysis of variance followed by Bonferroni’s test).

Because inhibition of the antiporter and blockade of the Na+ channels, as well as activation of H3R, attenuated anoxic NE release, we subsequently tested whether H3R stimulation might be coupled to inhibition of the NHE and/or to blockade of the Na+ channel. For this, we evaluated the effects of subthreshold concentrations of EIPA, HOE 642, TTX and imetit, alone and in combination. As shown in figure6, imetit at 30 nM (fig. 6, A–C), EIPA at 3 μM (fig. 6A), HOE 642 at 3 μM (fig. 6B) and TTX at 0.3 μM (fig. 6C) each failed to diminish anoxic NE release when tested alone. In contrast, when imetit was combined with EIPA (fig. 6A), HOE 642 (fig. 6B) or TTX (fig. 6C), maximum anoxic NE release was significantly decreased (i.e., by ∼50%).

Figure 6
Figure 6

Blockade of anoxic NE release from human right atrial tissue by the selective H3R agonist imetit in combination with the NHE inhibitors EIPA and HOE 642 (A and B) and the Na+ channel blocker TTX (C). In each panel, human atrial tissue was incubated without any drug (control) or with subthreshold concentrations of imetit (30 nM), EIPA (3 μM), HOE 642 (3 μM) and TTX (0.3 μM) either alone or in combination. Bars represent the total NE released into the incubation medium during 70 min of anoxia (mean ± S.E.M.; n = 6 for A, n = 7 for B and n = 5 for C; ** P < .01vs. control by analysis of variance followed by Bonferroni’s test).

Anoxia and histamine release from the human myocardium.

As shown in figure 5, A and B, the selective H3R antagonists thioperamide and clobenpropit each alone increased maximum anoxic NE release by 25% to 30%. Because this suggested that H3R become activated in anoxic conditions, we next assessed whether anoxia promotes histamine release from the human myocardium. To prevent histamine destruction, human right atrial tissue was incubated with the histamine N-methyl transferase inhibitor SKF-91,488 (10 μM; Imamuraet al., 1994). After 70 min of anoxia, histamine release into the incubation medium increased by 33% over matched normoxic controls (929 ± 121 vs. 698 ± 65 pmol/g,n = 15, P < .05 by paired t test). SKF-91,448 did not influence NE release: anoxic NE release was ∼7-fold greater than in normoxic conditions, whether in the presence (data not shown, n = 15) or absence (fig. 1) of SKF-91,448.

Discussion

Our findings indicate that activation of prejunctional H3R suppresses carrier-mediated NE release in a human model of protracted myocardial ischemia and suggest that this action is associated with an inhibition of Na+ accumulation in sympathetic nerve endings.

Exposure of human atrial myocardium to protracted anoxia, instituted by replacement of oxygen with nitrogen, lack of glucose and introduction of a reducing agent (Kurz et al., 1995), elicited a massive release of endogenous NE, which progressively increased in a time-dependent fashion, reaching a maximum plateau after 70 min of exposure. The neuronal NE transporter blocker DMI inhibited the anoxic NE release, a strong indication that this release was carrier mediated (Imamura et al., 1996). Notably, when NE release is exocytotic, DMI potentiates it (Imamura et al., 1994); in fact, we found that DMI potentiated NE release only at the beginning of anoxia (see fig. 1). In contrast to NE exocytosis, which is associated with acute myocardial ischemia (Imamura et al., 1994), carrier-mediated NE release occurs in protracted ischemia, when metabolically deprived ion pumps fail and protons accumulate in sympathetic nerve endings, leading to a compensatory NHE activation and intracellular Na+ accumulation (Dart and Du, 1993;Schömig, 1990). This, coupled with a decreased vesicular storage of NE and its consequent accumulation in the axoplasm, causes a reversal of the NE neuronal uptake (uptake1), such that large amounts of NE are actively transported out of the sympathetic nerve terminal (carrier-mediated NE release) (Dart and Du, 1993;Imamura et al., 1996; Kurz et al., 1995;Schömig, 1990).

We found that two different NHE inhibitors, EIPA (Vigne et al., 1983) and HOE 642 (Russ et al., 1996), inhibited anoxic NE release, suggesting that activation of the antiporter was involved in the Na+ accumulation in sympathetic nerve endings. Also, voltage-dependent Na+ channels most likely contributed to the intraneuronal accumulation of Na+ in anoxic conditions, and thus to the reversal of the NE transporter. Accordingly, the Na+-channel blocker TTX (Hille, 1992) decreased anoxic NE release, whereas aconitine, which is known to prolong Na+ channel conductance (Hille, 1992), potentiated it. The fact that anoxic NE release was sensitive to TTX does not necessarily imply that exocytosis played a role in the anoxic release process (Münch et al., 1996). Indeed, as previously indicated, if an exocytotic process had been involved, DMI would have potentiated it (Imamura and Levi, 1995). We found that DMI enhanced NE release only at the beginning of anoxia, when exocytosis is known to play a role (Imamura et al., 1994). In contrast, DMI markedly antagonized NE release after 50 and 70 min of anoxia (figs. 1and 2B). Thus, in this ischemic human model, exocytosis plays only a minor, initial role in the release of NE, whereas reversal of the neuronal transporter in an outward direction is the predominant long-term mechanism of the massive NE release that characterizes protracted anoxia.

The selective H3R agonist imetit (Garbarg et al., 1992) markedly attenuated anoxic NE release, an effect that was prevented by the H3R antagonists thioperamide (Arranget al., 1987) and clobenpropit (Barnes et al., 1993; Kathmann et al., 1993). Thus, our findings indicate that activation of H3R inhibits carrier-mediated NE release. Having previously demonstrated that H3R are located on sympathetic nerve endings in the human heart (Imamuraet al., 1995), we suggest that the adrenergic nerve terminal is the site at which H3Rs inhibit carrier-mediated NE release in this human model of protracted myocardial ischemia. Because H3R activation, unlike DMI, does not inhibit the neuronal uptake of NE (Imamura et al., 1994), the inhibition of carrier-mediated NE release by H3R must involve other mechanisms—possibly, a reduction in intraneuronal Na+accumulation.

Such reduction could result from an association between H3R activation and inhibition of NHE. Indeed, we found that subthreshold concentrations of imetit and EIPA, as well as subthreshold concentrations of imetit and HOE 642, acted synergistically to significantly reduce anoxic NE release when added in combination. Furthermore, subthreshold concentrations of imetit and TTX also acted synergistically to inhibit anoxic NE release. Thus, activation of H3R appears to result in an inhibition of both NHE and voltage-dependent Na+ channels.

H3Rs are likely coupled to a pertussis toxin-sensitive Gi/Go protein and effect a reduction in Ca++ current in cardiac sympathetic nerve endings, thus attenuating NE exocytosis in acute myocardial ischemia (Endou et al., 1994; Imamura et al., 1994). Because exocytosis is PKC dependent (Greengard, 1987; Imamura et al., 1995) and H3R activation seemingly inhibits phosphoinositide metabolism (Cherifi et al., 1992), this would in turn decrease PKC activity. Thus, PKC inhibition could play an important role in the H3R-mediated attenuation of NE release in acute myocardial ischemia. Furthermore, because PKC activation is known to stimulate NHE (Wakabayashi et al., 1997), an H3R-mediated decrease in PKC activity would be expected to inhibit NHE. Accordingly, we had proposed that in protracted myocardial ischemia in the isolated guinea pig heart, the reduction of carrier-mediated NE release associated with H3R activation may result from an inhibition of NHE in sympathetic nerve endings, secondary to phosphoinositide turnover inhibition and consequent decrease in PKC activity (Imamura et al., 1996). The same mechanism could apply to the H3R-mediated inhibition of carrier-mediated NE release in the present human model of protracted myocardial ischemia.

It is conceivable that a reduction in PKC activity may also mediate the H3R-induced inhibition of voltage-dependent Na+channels. PKC activation, which is likely to occur with hypoxia (Juet al., 1996), is known to slow Na+ current inactivation rate and increase Na+ channel open probability (Numann et al., 1994). Accordingly, PKC inhibition would decrease the intraneuronal accumulation of Na+ in anoxic conditions. Another possibility is that Gi-coupled H3Rs reduce intraneuronal cAMP levels by inhibiting adenylyl cyclase; this would likely decrease PKA activity. Because PKA stimulates NHE-1 and NHE-2 (Kandasamy et al., 1995) and enhances Na+ current through voltage-operated Na+ channels (Levitan, 1994), a decrease in PKA activity could reduce the intraneuronal accumulation of Na+ and, thus, carrier-mediated NE release. Notably, HOE 642 is a selective inhibitor of NHE-1 (Scholz et al., 1995), the predominant NHE isoform in the heart (Loh et al., 1996), whereas NHE-3, which is inhibited by PKC (Tse et al., 1993) and PKA (Moeet al., 1995), is not expressed in the heart (Tse et al., 1993).

Because thioperamide and clobenpropit each alone potentiated anoxic NE release, H3Rs must become activated in anoxic conditions. This presupposes the enhanced availability of an endogenous H3R ligand in protracted ischemia. Indeed, we found that histamine release was significantly increased in anoxic conditions, suggesting that cardiac adrenergic nerve endings are exposed to functionally significant concentrations of this amine in protracted ischemia, which is in keeping with the very high affinity of H3R for histamine (KD = 5 nM) (Hillet al., 1997). Inasmuch as H1 and H2histamine receptors have a relatively low affinity for histamine (KD ∼10 μM) (Hill et al., 1997), it is conceivable that depending on the amounts released, endogenous histamine may have antiarrhythmic or arrhythmogenic effects due to H3R-mediated decrease of NE release (Imamura et al., 1996) or activation of H1/H2receptors (Levi et al., 1991), respectively.

Although an enhanced histamine release in myocardial ischemia/reperfusion had already been described in cavian and canine hearts (Imamura et al., 1994, 1996; Levi et al., 1991; Wolff and Levi, 1986, 1988), and an increase in mast cell number and histamine content had been reported in the human heart as a result of ischemia (Forman et al., 1985; Kalsner and Richards, 1984), this is the first demonstration that sufficient histamine is released in the ischemic human heart to activate H3R on sympathetic nerve endings and thus attenuate carrier-mediated NE release.

In view of our previous findings in the guinea pig heart (Imamuraet al., 1994, 1996), dog ventricular myocardium (Seyediet al., 1996) and human atrium (Imamura et al., 1995), H3Rs are most likely present on sympathetic nerve endings in human ventricle. Therefore, our discovery that endogenous histamine, released in a human model of protracted myocardial ischemia, activates H3Rs on sympathetic nerve endings may be clinically relevant. In an ischemia/reperfusion model in the guinea pig, we previously found that NE release directly correlates with the severity of reperfusion arrhythmias and H3R activation reduces NE release and the incidence of ventricular fibrillation by 50% (Imamura et al., 1996). In humans, myocardial infarction is often accompanied by arrhythmias that can be fatal (Braunwald and Sobel, 1988). Sympathetic overactivity and excessive NE release may increase metabolic demand, thus aggravating the primary ischemia and initiating a vicious cycle leading to further myocardial damage (Kübler and Strasser, 1994). Indeed, increased plasma NE levels are a powerful predictor for the development of cardiac failure, angina, myocardial infarction and mortality (Benedict et al., 1996). Therefore, reduction in NE release from cardiac sympathetic nerves is a pivotal protective mechanism. Our findings indicate that H3Rs are likely to mitigate the consequences of sympathetic overactivity in the ischemic human heart and suggest new therapeutic strategies to alleviate dysfunctions associated with myocardial ischemia.

Acknowledgments

We gratefully acknowledge the help of the Surgical and Nursing Staff of the Department of Cardiothoracic Surgery, New York Hospital-Cornell Medical Center, in providing us with surgical specimens of human right atrium. We thank Drs. Harry M. Lander and Michiaki Imamura for helpful criticism.

This article is dedicated to Emeritus Professor Alberto Giotti.

Footnotes

  • Send reprint requests to: Roberto Levi, M.D., Department of Pharmacology, Cornell University Medical College, 1300 York Avenue, New York, NY 10021. E-mail: rlevi{at}med.cornell.edu.

  • ↵1 This work was supported by National Institutes of Health, Grants HL34215 and HL4603.

  • ↵2 Preliminary data were presented at the 69th Scientific Sessions of the American Heart Association, New Orleans, LA, November 10–13, 1996, and published in abstract form [Circulation 94 (suppl I): I-474, 1996].

  • ↵3 Current affiliation: Department of Cardiovascular Surgery, Hokkaido University School of Medicine, Sapporo, Japan.

  • Abbreviations:
    DMI
    desmethylimipramine (desipramine)
    EIPA
    5-(N-ethyl-N-isopropyl)-amiloride
    H3R
    histamine H3 receptor
    NE
    norepinephrine
    NHE
    Na+-H+ exchanger
    PKA
    protein kinase A
    PKC
    protein kinase C
    TTX
    tetrodotoxin
    KHS
    Krebs-Henseleit Solution
    DMSO
    dimethylsulfoxide
    • Received March 20, 1997.
    • Accepted July 25, 1997.

References

  1. ↵
    1. Arrang J. M.,
    2. Garbarg M.,
    3. Lancelot J. C.,
    4. LeComte J. M.,
    5. Pollard H.,
    6. Robba M.,
    7. Schunack W.,
    8. Schwartz J. C.
    (1987) Highly potent and selective ligands for histamine H3-receptors. Nature 327:117–123.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Barnes J. C.,
    2. Brown J. D.,
    3. Clarke N. P.,
    4. Clapham J.,
    5. Evans D. J.,
    6. O’Shaughnessy C.
    (1993) T. Pharmacological activity of VUF 9153, an isothiourea histamine H3 receptor antagonist. Eur. J. Pharmacol. 250:147–152.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Beaven M. A.,
    2. Shaff R. E.
    (1979) New inhibitors of histamine-N-methyltransferase. Biochem. Pharmacol. 28:183–188.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Benedict C. R.,
    2. Shelton B.,
    3. Johnstone D. E.,
    4. Francis G.,
    5. Greenberg B.,
    6. Konstam M.,
    7. Probstfield J. L.,
    8. Yusuf S.
    (1996) Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. Circulation 94:690–697.
  5. ↵
    1. Braunwald E.
    1. Braunwald E.,
    2. Sobel B. E.
    Coronary blood flow and myocardial ischemia. in Heart Disease: A Textbook of Cardiovascular Medicine, ed Braunwald E. (W. B. Saunders, Philadelphia), pp 1191–1221.
  6. ↵
    1. Cherifi Y.,
    2. Pigeon C.,
    3. Le Romancer M.,
    4. Bado A.,
    5. Reyl-Desmars F.,
    6. Lewin M. J. M.
    (1992) Purification of a histamine H3 receptor negatively coupled to phosphoinositide turnover in the human gastric cell line HGT1. J. Biol. Chem. 267:25315–25320.
  7. ↵
    1. Dart A. M.,
    2. Du X.-J.
    (1993) Unexpected drug effects on autonomic function during myocardial ischaemia. Cardiovasc. Res. 27:906–914.
    OpenUrlFREE Full Text
  8. ↵
    1. Endou M.,
    2. Poli E.,
    3. Levi R.
    (1994) Histamine H3-receptor signaling in the heart: Possible involvement of Gi/Go proteins and N-type Ca++ channels. J. Pharmacol. Exp. Ther. 269:221–229.
  9. ↵
    1. Forman M. B.,
    2. Oates J. A.,
    3. Robertson D.,
    4. Robertson R. M.,
    5. Roberts L. J., 2d,
    6. Virmani R.
    (1985) Increased adventitial mast cells in a patient with coronary spasm. N. Engl. J. Med. 313:1138–1141.
  10. ↵
    1. Garbarg M.,
    2. Arrang J. M.,
    3. Rouleau A.,
    4. Ligneau X.,
    5. Tuong M. D.,
    6. Schwartz J. C.,
    7. Ganellin C. R.
    (1992) S-[2-(4-Imidazolyl)ethyl]isothiourea, a highly specific and potent histamine H3 receptor agonist. J. Pharmacol. Exp. Ther. 263:304–310.
  11. ↵
    1. Greengard P.
    (1987) Neuronal phosphoproteins: Mediators of signal transduction. Mol. Neurobiol. 1:81–119.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Hill S. J.,
    2. Ganellin C. R.,
    3. Timmerman H.,
    4. Schwartz J. C.,
    5. Shankley N. P.,
    6. Young J., M.,
    7. Schunack W.,
    8. Levi R.,
    9. Haas H. L.
    (1997) International Union of Pharmacology. XIII. Classification of Histamine Receptors. Pharmacol. Rev. 49:253–278.
  13. ↵
    1. Hille B.
    Ionic Channels of Excitable Membranes (Sinauer Associates Inc. Sunderland, MA), pp 1–607.
  14. ↵
    1. Imamura M.,
    2. Poli E.,
    3. Omoniyi A. T.,
    4. Levi R.
    (1994) Unmasking of activated histamine H3 receptors in myocardial ischemia: Their role as regulators of exocytotic norepinephrine release. J. Pharmacol. Exp. Ther. 271:1259–1266.
  15. ↵
    1. Imamura M.,
    2. Seyedi N.,
    3. Lander H. M.,
    4. Levi R.
    (1995) Functional identification of histamine H3-receptors in the human heart. Circ. Res. 77:206–210.
  16. ↵
    1. Imamura M.,
    2. Lander H. M.,
    3. Levi R.
    (1996) Activation of histamine H3 receptors inhibits carrier-mediated norepinephrine release during protracted myocardial ischemia: Comparison with adenosine A1 receptors and α2-adrenoceptors. Circ. Res. 78:475–481.
  17. ↵
    Imamura, M. and Levi, R.: Bradykinin promotes exocytotic and carrier-mediated norepinephrine release in myocardial ischemia-reperfusion (Abstract). Circulation 92: suppl I, I-568, 1995..
  18. ↵
    1. Ju Y. K.,
    2. Saint D. A.,
    3. Gage P. W.
    (1996) Hypoxia increases persistent sodium current in rat ventricular myocytes. J. Physiol. (Lond.) 497:337–347.
  19. ↵
    1. Kalsner S.,
    2. Richards R.
    (1984) Coronary arteries of cardiac patients are hyperreactive and contain stores of amines: A mechanism for coronary spasm. Science 223:1435–1437.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Kandasamy R. A.,
    2. Yu F. H.,
    3. Harris R.,
    4. Boucher A.,
    5. Hanrahan J. W.,
    6. Orlowski J.
    (1995) Plasma membrane Na+/H+ exchanger isoforms (NHE-1, -2, and -3) are differentially responsive to second messenger agonists of the protein kinase A and C pathways. J. Biol. Chem. 270:29209–29216.
  21. ↵
    1. Kathmann M.,
    2. Schlicker E.,
    3. Detzner M.,
    4. Timmerman H.
    (1993) Nordimaprit, homodimaprit, clobenpropit and imetit: Affinities for H3 binding sites and potencies in a functional H3 receptor model. Naunyn-Schmiedeberg’s Arch. Pharmacol. 348:498–503.
    OpenUrlPubMed
  22. ↵
    1. Kurz T.,
    2. Richardt G.,
    3. Hagl S.,
    4. Seyfarth M.,
    5. Schömig A.
    (1995) Two different mechanisms of noradrenaline release during normoxia and simulated ischemia in human cardiac tissue. J. Mol. Cell. Cardiol. 27:1161–1172.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Kübler W.,
    2. Strasser R. H.
    (1994) Signal transduction in myocardial ischaemia. Eur. Heart J. 15:437–445.
    OpenUrlFREE Full Text
  24. ↵
    1. Uvnas B.
    1. Levi R.,
    2. Rubin L. E.,
    3. Gross S. S.
    Histamine in cardiovascular function and dysfunction: recent developments. in Handbook of Experimental Pharmacology, Vol. 97: Histamine and Histamine Antagonists. ed Uvnas B. (Springer-Verlag, Berlin/Heidelberg), pp 347–383.
  25. ↵
    1. Levitan I. B.
    (1994) Modulation of ion channels by protein phosphorylation and dephosphorylation. Annu. Rev. Physiol. 56:193–212.
  26. ↵
    1. Loh S. H.,
    2. Sun B.,
    3. Vaughan-Jones R. D.
    (1996) Effect of Hoe 694, a novel Na+-H+ exchange inhibitor, on intracellular pH regulation in the guinea-pig ventricular myocyte. Br. J. Pharmacol. 118:1905–1912.
  27. ↵
    1. Moe O. W.,
    2. Amemiya M.,
    3. Yamaji Y.
    (1995) Activation of protein kinase A acutely inhibits and phosphorylates Na/H exchanger NHE-3. J. Clin. Invest. 96:2187–2194.
  28. ↵
    1. Münch G.,
    2. Kurz T.,
    3. Urlbauer T.,
    4. Seyfarth M.,
    5. Richardt G.
    (1996) Differential presynaptic modulation of noradrenaline release in human atrial tissue in normoxia and anoxia. Br. J. Pharmacol. 118:1855–1861.
  29. ↵
    1. Numann R.,
    2. Hauschka S. D.,
    3. Catterall W. A.,
    4. Scheuer T.
    (1994) Modulation of skeletal muscle sodium channels in a satellite cell line by protein kinase C. J. Neurosci. 14:4226–4236.
  30. ↵
    1. Russ U.,
    2. Balser C.,
    3. Scholz W.,
    4. Albus U.,
    5. Lang H. J.,
    6. Weichert A.,
    7. Schölkens B. A.,
    8. Gögelein H.
    (1996) Effects of the Na+/H+-exchange inhibitor Hoe 642 an intracellular pH, calcium and sodium in isolated rat ventricular myocytes. Pflugers Arch. 433:26–34.
    OpenUrlCrossRefPubMed
  31. ↵
    1. Scholz W.,
    2. Albus U.,
    3. Counillon L.,
    4. Gogelein H.,
    5. Lang H. J.,
    6. Linz W.,
    7. Weichert A.,
    8. Schölkens B. A.
    (1995) Protective effects of HOE642, a selective sodium-hydrogen exchange subtype 1 inhibitor, on cardiac ischaemia and reperfusion. Cardiovasc. Res. 29:260–268.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Schömig A.
    (1990) Catecholamines in myocardial ischemia: Systemic and cardiac release. Circulation 82:13–22.
    OpenUrl
  33. ↵
    Seyedi, N., Imamura, M., Hatta, E. and Levi, R.: Desensitization of histamine H3 receptors in a canine model of pacing-induced heart failure: A cause of increased norepinephrine release (Abstract)? Circulation 94: suppl I, I-406, 1996..
  34. ↵
    1. Tse C. M.,
    2. Levine S. A.,
    3. Yun C. H.,
    4. Brant S. R.,
    5. Pouyssegur J.,
    6. Montrose M. H.,
    7. Donowitz M.
    (1993) Functional characteristics of a cloned epithelial Na+/H+ exchanger (NHE3): Resistance to amiloride and inhibition by protein kinase C. Proc. Natl. Acad. Sci. U.S.A. 90:9110–9114.
  35. ↵
    1. Vigne P.,
    2. Frelin C.,
    3. Cragoe E., J., Jr.,
    4. Lazdunski M.
    (1983) Ethylisopropyl-amiloride: A new and highly potent derivative of amiloride for the inhibition of the Na+/H+ exchange system in various cell types. Biochem. Biophys. Res. Commun. 116:86–90.
    OpenUrlCrossRefPubMed
  36. ↵
    1. Wakabayashi S.,
    2. Shigekawa M.,
    3. Pouyssegur J.
    (1997) Molecular physiology of vertebrate Na+/H+ exchangers. Physiol. Rev. 77:51–74.
  37. ↵
    1. Wolff A. A.,
    2. Levi R.
    (1986) Histamine and cardiac arrhythmias. Circ. Res. 58:1–16.
  38. ↵
    1. Wolff A. A.,
    2. Levi R.
    (1988) Ventricular arrhythmias parallel cardiac histamine efflux after coronary artery occlusion in the dog. Agents Actions 25:296–306.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

OtherCARDIOVASCULAR PHARMACOLOGY

Activation of Histamine H3 Receptors Inhibits Carrier-Mediated Norepinephrine Release in a Human Model of Protracted Myocardial Ischemia ,

Eiichiro Hatta, Keishu Yasuda and Roberto Levi
Journal of Pharmacology and Experimental Therapeutics November 1, 1997, 283 (2) 494-500;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo

Jump to section

Advertisement